The Women's Oncology Program (WON) aims to stimulate high quality basic, translational, and clinical research and trials in women's cancers through collaborations, program interactions, information sharing, and faculty recruitment, and to translate the research findings into cutting edge diagnostics and treatments for cancer. Leaders of the Women's Oncology program include Margaret A. Shupnik, PhD, Professor of Medicine and Physiology, an expert in molecular endocrinology and estrogen receptor action; Susan C. Modesitt. MD, Professor of Obstetrics and Gynecology, an expert in gynecology-oncology clinical trials; and Joellen M. Schildkraut, PhD, MPH Professor of Public Health Sciences, an expert in the genetics and epidemiology of women's cancers, particularly breast and ovarian cancer. WON represents a wide variety of intellectual, technical, and clinical expertise with 25 members from 10 different basic science and clinical departments in the School of Medicine and School of Engineering and Applied Science, and 3 associate members. Cancer Center support for faculty recruitment and retention, forums for information exchange such as the Cancer Center Seminar Series, Women's Oncology monthly research meetings and Program Retreat, Cancer Center pilot research funds, and support for and from our Shared Resources have enabled the success of our research programs, which have become increasingly cancer-focused and interactive. The high quality of the resulting science resulted in numerous high impact publications, including 22% inter- programmatic and 18% intra-programmatic publications over the past 5 years. Current funding is over $4.5M, including $2M in NCI funding, and patient accrual was robust for patients with Breast (17.5%) and Ovarian (45.8%) cancers in 2015. With over 300,000 new diagnoses of these cancers yearly in the United States, it remains essential to develop new treatments for cancers resistant to current therapeutic approaches, methods for early detection and prognostic indicators for responses, and methods to assess risk and prevent breast and gynecological cancers. The WON program has developed specific aims and transdisciplinary groups of investigators to tackle these critical issues in women's cancers.
Aim 1 : To investigate pathways of therapeutic resistance in women's cancers and identify prognostic indicators and new molecular targets.
Aim 2 : To understand how dysregulation of metabolism and obesity contribute to women's cancers and identify potential new therapeutic targets.
Aim 3. To identify behavioral, hormonal and genetic risks for women's cancers, and improve detection methods for these cancers.
Each aim i ncludes basic, translational and clinical research and trials that cut across all women's cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-28
Application #
9626889
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
28
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Melhuish, Tiffany A; Kowalczyk, Izabela; Manukyan, Arkadi et al. (2018) Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim Biophys Acta Gene Regul Mech 1861:983-995
Stowman, Anne M; Hickman, Alexandra W; Mauldin, Ileana S et al. (2018) Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res 28:237-245
Carlton, Anne L; Illendula, Anuradha; Gao, Yan et al. (2018) Small molecule inhibition of the CBF?/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition. Gynecol Oncol 149:350-360
Kulling, Paige M; Olson, Kristine C; Olson, Thomas L et al. (2018) Calcitriol-mediated reduction in IFN-? output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation. J Steroid Biochem Mol Biol 177:140-148
Borten, Michael A; Bajikar, Sameer S; Sasaki, Nobuo et al. (2018) Automated brightfield morphometry of 3D organoid populations by OrganoSeg. Sci Rep 8:5319
Olson, Kristine C; Kulling Larkin, Paige M; Signorelli, Rossana et al. (2018) Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. Cytokine 111:551-562
Pfister, Katherine; Pipka, Justyna L; Chiang, Colby et al. (2018) Identification of Drivers of Aneuploidy in Breast Tumors. Cell Rep 23:2758-2769
Carhart, Miev Y; Schminkey, Donna L; Mitchell, Emma M et al. (2018) Barriers and Facilitators to Improving Virginia's HPV Vaccination Rate: A Stakeholder Analysis With Implications for Pediatric Nurses. J Pediatr Nurs 42:1-8
Hao, Yi; Bjerke, Glen A; Pietrzak, Karolina et al. (2018) TGF? signaling limits lineage plasticity in prostate cancer. PLoS Genet 14:e1007409
Obeid, Joseph M; Kunk, Paul R; Zaydfudim, Victor M et al. (2018) Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother 67:161-174

Showing the most recent 10 out of 539 publications